Archive | Next Phase Archive RSS feed for this section

The Digital RESI Europe Experience

10 Mar

By Gregory Mannix, Chief Conference Officer, Vice President International Business Development, LSN

The program guide and the “live” agenda will navigate you to the right RESI event and meeting.

A typical RESI conference attendee in the physical world receives the program guide and uses the agenda to plan out their day. So, the first hurdle for the digital event is how to navigate through a virtual conference? LSN is taking the “agenda page” of the Digital RESI Europe program guide and making it an interactive navigation vehicle for the three-day virtual event. All attendees will have 24/7 access to the RESI investor and workshop panels, Innovation Challenge finalist presentations, Featured Company Pitches, Exhibitor portal and, most importantly, an enhanced and expanded Partnering Platform.

The Digital RESI Europe Agenda. https://www.resiconference.com/resiagenda/

LSN is going to embed links throughout the agenda that will allow RESI Europe attendees to easily navigate through all the aspects of the virtual conference. This means more opportunity to get at the amazing content presented by the who’s who of early stage global partnering. Click on the panel or workshop you wish to attend, and you will be connected to a prerecorded panel video. Click on the Partnering Platform of the agenda and be linked to a new enhanced partnering software powered by Meeting Mojo for your live video conference with screen sharing functionality. As compared to the standard 1-day physical conference, Digital RESI Europe Partnering has now been expanded to 12 hours per day over 3 days for you to maximize your number of meetings. Click on the company presentation you want to see/hear, and the prerecorded video will surface for your viewing pleasure. Click on the Exhibition Portal and see the 30 top ranked Innovation Challenge companies and meet all of our featured exhibitors and tech hubs.

LSN is fortunate in that for Digital RESI Europe to succeed, LSN must stick to our core value, which is matching early stage companies with early stage partners and facilitating 1:1 partnering meetings. If we get that bit right, we will have preserved our value. LSN is confident that the virtual meeting scenario will be a success and may be a new way to connect buyers and sellers!

1:1 Partnering Meetings

Digital RESI Europe is a dedicated global partnering event. RESI has the most powerful partnering platform because we can match companies and partners based on stage of development and product fit. The core value is our 1:1 partnering, that RESI has used since 2013. The partnering software is owned and operated by our partner Meeting Mojo, which is implementing a video meeting component embedded in the application. Any RESI attendee can use this video capability to “attend” their scheduled meeting. The challenge for all the attendees will be the geographic time zone issues and that may require some flexibility. Fortunately, being virtual and being able to extend the conference from a one day physical to a three-day virtual conference means more availability to find mutual time slots that will work for both parties.

Investor and Workshop Panels

RESI is unique in that we dedicate most of our panels to the ten categories of investors and partners who play in the early-stage space, cross-border and across the silos of drugs, devices, diagnostics and digital health. What attendees learn from these panels is who the right players are, the best way to reach out, how they source technology (including RESI), how they vet companies and how they help early stage companies with whom they have relationships develop. The information that entrepreneurs receive from these panels is invaluable in helping them understand the nuances of how all the different players in the space approach early stage startups.

 

Featured Company Pitch Session Presenting Companies

Early stage life science companies that are actively raising seed capital ($25k to 2 MM), Series A ($2 MM to 10 MM) or Series B ($10 MM to 50 MM) use RESI to get in front of a panel of qualified investors in their market segment and pitch their company and product. The investors ask questions, provide feedback and commentary on the pitch, company and product. These presentations are invaluable in the journey to raising capital. Digital RESI Europe will feature presenting companies prominently on the conference website, and program guide and will post a prerecorded version of their pitch. Investors and industry experts will be encouraged to submit written questions to the pitching companies.

LSN Created a Virtual Exhibitor Hall

The Exhibition Portal will feature all our Digital RESI Europe exhibitors and our Innovation Challenge finalists.

Innovation Challenge

RESI is world renowned for its Innovation Challenge where, at every RESI conference, we feature select companies that have been scored and ranked with the LSN expert system for “investability.” We take the top 30 firms who apply and feature them with an easel in the exhibition hall. LSN has created a virtual exhibition hall where partners can see their poster board and also hear them give a prerecorded 3-5-minute pitch on their technology. The Innovation Challenge participants are virtually voted on with “RESI cash” and the winners will be awarded prizes and get featured in the LSN weekly newsletter.

Virtual Exhibitor Hall

The RESI exhibitors and sponsors will be featured on a dedicated page with a virtual exhibitor booth, showcasing their services and the value they can provide. Participating tech hubs can highlight their programs and constituent companies.

DIGITAL RESI EUROPE – FAQ

10 Mar

By Karen Deyo, Senior Investor Research Analyst, LSN

How exactly will Digital RESI Europe work?

LSN is going to embed links throughout The RESI Europe Agenda that will allow Digital RESI Europe attendees to easily navigate through all the aspects of the virtual conference. This means more opportunity to get at the amazing content presented by the who’s who of early stage global partnering. At their discretion attendees can now immerse themselves in ALL the content being delivered, and have more time to engage with participating companies and investors.

Will the panels and workshops be available over the three days?

Yes, attendees will have full virtual access to navigating all components of the conference over these three days. Not only will you be able to see “day of” content but also past panels where you can hear firsthand, how these investors and strategic partners source, vet and develop relationships with early stage technology firms.

How will Investor and Workshop panels be presented?

LSN is taking the “agenda page” of the RESI Europe program guide and making it an interactive navigation vehicle for the three-day virtual event. All attendees will have 24/7 digital access to the full day of panels scheduled in the agenda. At the click of a button attendees will be able to review pre-recorded panel discussions at their convenience. LSN will also provide access to past RESI panels of investors and strategic partners explaining their investment mandates for the 4Ds, drugs, devices, diagnostics, and digital health. In addition to providing access to the scheduled panels as well as content from previous RESI conferences, attendees have the additional flexibility of working around scheduled meetings without struggling to balance their schedule.

Is RESI still doing 1:1 partnering?

Yes. Because Digital RESI Europe is now virtual, LSN can extend RESI 1:1 Partnering from one physical day to three virtual days. This will give you more opportunity to arrange more partnering meetings. The RESI Partnering Platform will allow for video conferencing and screen sharing to make your meetings more effective.

Will RESI partnering cover the three virtual days?

Yes. Digital RESI Europe attendees will be able to take advantage of more than three times as many partner meeting slots, have more opportunity to see relevant partner content and the ability to pick and choose meetings, panels and workshops from the comfort of your home or office.

I go to RESI to meet investors and strategic partners – how will that be affected?

RESI is unique in that it is a dedicated partnering conference. At any given RESI conference, LSN will have between 300 and 600 entrepreneurs and, amazingly, the same number of investors, making for a 1:1 ratio of buyers and sellers. The core value is the capability to utilize the RESI Partnering Platform (powered by Meeting Mojo) for an early stage life science company to meet investors and partners that are a fit for their stage of development and their product set. This makes for compelling, dynamic meetings based on fit.

RESI has been working with Meeting Mojo for RESI as a proprietary partnering software since LSN started the RESI Conference series back in 2013. Originally, LSN jointly designed and developed a capability to match the scientist-entrepreneurs and fundraising CEOs with investors and strategic partners based on data parameters in each parties’ profile. The partnering system includes detailed company profiles, preventing meetings where attendees spend the time discovering they are not a fit for each other, wasting a valuable time slot. RESI partnering stands out in the industry because mismatching is dramatically reduced, ensuring maximum value of your partnering schedule. The three day Digital RESI Europe format will allow attendees to take even more advantage of this unique LSN resource.

Please explain how the Meeting Mojo video software partnering module will work?

We are all familiar with video conferencing and video meetings via our PC applications and mobile cell devices, so this is not a big leap to integrate the video capability into the Meeting Mojo partnering and scheduling software. Most RESI attendees are already familiar with the Meeting Mojo/RESI partnering. You log in as you have in the past and schedule your meetings as before, and at the designated time of your meeting you simply go to the Meeting Mojo partnering site and with a few mouse clicks will be “live” for your partnering meeting.

The virtual meeting platform is seamlessly integrated into the partnering software, and LSN and Meeting Mojo will make step-by-step instructions available. It is easy to use, intuitive and very good quality. We can use Meeting Mojo partnering software to provide a functional equivalent of the physical 1:1 meeting that make RESI a very important global event.

RESI Europe 2020 Innovation Challenge – Check Out the Finalists!

5 Mar

By Claire Jeong, Director of Research, Asia BD, LSN

claire

With less than 3 weeks left until our second RESI Europe conference, we are very excited to announce the RESI Europe Innovation Challenge finalists. The RESI team received applications from all across the globe, boasting an even stronger diversity than our inaugural RESI Europe in Vienna last year.

All registered RESI attendees will receive 5 “RESI Cash”, which they can use to “invest” in the most promising Innovation Challenge companies. As always, we highly encourage all attendees to reserve some time during the conference to browse around the exhibit hall and engage with the finalists who will be eager to pitch their company and the innovative work they are doing to address unmet medical needs.

Thank you for everyone who applied for the Innovation Challenge. For those of you who were not selected, please look out for future opportunities including RESI San Diego (June) and RESI Boston (September).

Congratulations again to the selected RESI Europe Innovation Challenge companies – please see them below!

Therapeutics

 

Medical Device

Digital Health

Diagnostics

 

LSN Making Advances to Grow Its European Ecosystem

5 Mar

By Gregory Mannix, Vice President International Business Development, LSN

I have been spending a great deal of time in Europe developing the LSN European Ecosystem, and this culminated in bringing the RESI Conference Series to Europe for the first time in 2019. The second RESI Europe conference will take place in a few short weeks in Paris on March 23rd. Here is a snapshot of what I have learned from my travels over the last 18 months.

What I see is many early-stage life science companies with great technology, moving and developing within a mostly regional ecosystem. This includes investors, government agencies, angels, family offices, VCs, PEs and Pharma and Medtech players.  The inevitable result is a huge bottleneck in which startups can’t find nearly enough regional investment partners, forcing scientist-entrepreneurs who are looking to raise their series A and B rounds to look outside of the region.  The challenge is that most are not prepared for this change and struggle with cultural and business practice differences. This is where LSN comes in, with valuable insight through our Fundraising Bootcamps and by bringing the global-focused RESI Conference Series to Europe.

Europe has a vibrant early-stage community of startups across the 4 Ds: Drugs, Devices, Diagnostics and Digital Health. Within the broader life sciences sector, including CROs and other service providers, research institutions and investment firms, our data tracks over 5,000 such companies around Europe that we have broken down below. In addition, the role startups play in moving the industry forward is evidenced by the fact that 2/3 of the assets in therapeutics are still in development.

 

Below is a list of all of the locations where LSN has been holding our Fundraising Bootcamps over the past 18 months, where we have recruited, trained and held one-on-one coaching sessions at some of the main tech hubs in Europe.  All told, LSN has reached almost 600 companies in the last year through our on-site Bootcamps, helping these companies expand outside their regions and enter LSN’s global ecosystem.

 

Registration Now Open for Inaugural 4D Meets AI Conference

5 Mar

By Chris Kennedy, Vice President Strategic Initiatives, 4D Meets AI, LSN

chris headshot

Artificial Intelligence (AI) is a transformative force in healthcare industry. From hospital care to clinical research, drug development and insurance, AI applications are revolutionizing how the health sector works to reduce spending and improve patient outcomes.

Seeing such tremendous potential of AI in the life science and healthcare domains, LSN created the 4D Meets AI Conference. Registration is now open for the September 22, 2020 event to be held at the Copley Marriott, Boston. www.4dmeetsai.com

Stemming from our long-standing RESI conference series, 4D Meets AI will continue doing what LSN does best – connecting early-stage companies that develop cutting-edge AI technology in drugs, devices, diagnostics and digital health, the ‘4Ds,’ with the right investors and decision-makers in the industry.

The 4D Meets AI conference is organized around those early stage companies in the drugs, devices, diagnostics and digital health verticals that are advancing the state of the art by using new tools and methodologies that AI brings to this dynamic sector. The conference is first and foremost a partnering conference for both buyers and sellers of early stage companies leveraging the power of AI technology.

NIH Is Supporting Entrepreneurs To Address The Looming Public Health Crisis: Life Science Nation Interview with Todd Haim, Ph.D., Chief, Office of Small Business Research, National Institute on Aging, National Institutes of Health

27 Feb

Todd Haim

– By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Dennis Ford

Dennis Ford(DF): Todd, please tell us about your new position and what you are trying to accomplish?

Todd Haim(TH): I began working on small business grant programs at the National Institutes of Health (NIH) more than 10 years ago when I joined the National Cancer Institute (NCI) as an AAAS Science and Technology Policy Fellow. After 9 years at NCI, I was asked to lead the launch of a new Office of Small Business Research (OSBR) at the National Institute on Aging (NIA). NIA’s OSBR was created just over 1 year ago. It serves as the main coordinating office for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants that are awarded to companies working on solutions to address aging and aging-related diseases.

One exciting aspect of our work at NIA is that the Institute does not have a singular disease focus; rather, we are interested in wide variety of new technologies related to aging and older adults. OSBR’s key goals include strategic coordination of the SBIR/STTR programs across NIA’s Scientific Divisions and connecting with small businesses across the U.S. interested in NIA funding to develop promising innovative technologies. We are also responsible for developing programs and resources to enhance the success of our awardees and funding projects in areas that both meet NIA’s scientific priorities and are ripe for commercialization.

Although OSBR’s overall goal is to fund innovative new technologies that will improve health and quality of life in our rapidly aging population, we also hope to raise awareness of the small business programs among first-time applicants and individuals who would not typically apply for NIH funding.

DF: What kind of funding is available to scientist-entrepreneurs through your new office?

TH: Most small businesses interested in improving the health of older Americans can find a funding opportunity from NIA that’s right for them. Through OSBR, NIA participates in several funding opportunity announcements (FOAs) that fall into two general categories: omnibus and targeted solicitations. Almost all NIH Institutes and Centers (ICs) as well as other government agencies within the Department of Health and Human Services (e.g., Food and Drug Administration, Centers for Disease Control and Prevention, etc.) participate in the annual  Omnibus FOA, and applications are accepted three times per year. This FOA does not focus on a single disease area, rather, it focuses on any health-related small business innovation of interest to these agencies. If a proposal submitted through the omnibus FOA relates to NIA’s mission, it may be considered for assignment to NIA.

In contrast, NIA’s targeted small business FOAs are specifically focused on aging and related diseases including Alzheimer’s disease (AD) and AD-related dementias (ADRD). In July 2019, NIA released a broad funding opportunity to encourage applications for the development of technologies addressing AD/ADRD.

We also offer programs designed to provide additional funding and technical/business assistance to our funded companies and potential applicants. One example is I-Corps™ at NIH, which provides entrepreneurial training, mentoring, networking, and market research. The Concept to Clinic: Commercializing Innovation (C3i) entrepreneurial training program is designed for medical device innovators. And the Applicant Assistance Program provides first-time or previously unsuccessful SBIR/STTR applicants with a dedicated mentor and step-by-step coaching to maximize their chances of obtaining funding. Finally, the Commercial Readiness Pilot Program, provides technical and R&D assistance to businesses at a later stage in their development.

DF: Who are you seeking? Is there a particular indication you are currently looking to fund or are you opportunistic in the arena of aging?

TH: One area of particular focus for NIA, and the nation, is Alzheimer’s disease and related dementias. Because the prevalence of AD is predicted to triple within the next 3 decades, Congress has provided significant AD/ADRD funding that has enabled NIA to fund a greater diversity and variety of projects in this area to advance research into a treatment, prevention, or cure for these devastating disorders. NIA also welcomes grant proposals for technologies and innovations in the broader scientific areas around aging, such as fall detection, biomarkers, interventions to help older people maintain independence, research to understand the mechanisms of aging, and methodologies to treat conditions commonly associated with aging.

DF: Have you evaluated and funded any startups to date? If so, how many? Are there funds remaining?

TH: Currently, NIA is funding close to 200 unique startup companies through the SBIR/STTR programs; details are available in the NIH RePORTER database. As the overall NIA budget has increased over the past few years, the SBIR/STTR budget for NIA has also increased. For instance, the NIA SBIR/STTR budget in fiscal year (FY) 2013 was only $27.5 million. In FY 2019, that number was estimated to be over $100 million, which is nearly a four-fold increase over a 6-year period.

NIA has a diverse portfolio of funded technologies. Approximately 32% of our funded technologies are drugs/therapeutics, but we also fund medical devices, including monitoring (18%) and supportive (10%) technologies. Digital and mobile health applications (19%) are also growing in utility, so we are seeing more applications in this field. The remainder of our portfolio consists of research tools (9%), in vitro diagnostic tools (7%), and imaging tools (5%). However, the proportions of each type of technology in our portfolio fluctuate over time based on the applications submitted during each funding cycle.

DF: Do you have a message for any of the U.S. companies developing solutions within the aging arena?

TH: One of the key goals that NIA’s OSBR is trying to achieve is to not only target academic scientists-turned-entrepreneurs, but also small business owners who are less familiar the NIH grants process. Though we are facing a lack of awareness of our programs by this group, many of their technologies are still supporting the NIH mission.

I would like entrepreneurs in the aging sphere to know that they have my highest respect and admiration because they are working to address a looming public health crisis. The difficulties that the biomedical enterprise has had in successfully targeting aging and AD point to the importance of NIH’s efforts to fund early-stage, meritorious projects being undertaken by startups and translational researchers. At NIH, it is our mission to invest in research and innovation that will ultimately benefit the health of everyone, and we encourage all eligible businesses developing aging-related technologies to apply for our small business grants. You are doing incredible work, and we are here to support you every step of the way. We encourage potential applicants to connect and seek guidance from us ahead of submitting an application and can be reached at niasmallbusiness@mail.nih.gov.

RESI Europe: New Top Investor Speakers Added

27 Feb

By Jessica Yang, Investor Research Analyst, LSN

In addition to RESI’s industry-leading one-on-one partnering experience, RESI Panels provide a great chance for entrepreneurs to hear insights from experienced investors as well as direct interaction opportunities with these speakers. Every panel will be a 50-minute moderated discussion in which the audience can be involved as well asking questions as the panelists discuss and move from topic to topic. RESI Europe will also feature different panels focused on informing entrepreneurs on how to go about raising capital for their life science technologies. Check below to see our updated speakers that will participate in RESI Europe in Paris on March 23, 2020.

 


Adriaan Hart de Ruijter
Managing Director
Cascara Ventures

Allan Daisley
Managing Director
Startupbootcamp
Digital Health Miami

Amine Benmoussa
Founding Partner
Apogee Ventures

Arpita Maiti
Executive Director & Global Head, Emerging Science & Innovation Lead, Inflammation & Immunology
Pfizer, Inc

Baudouin Hue
Partner
CapDecisif Management

Ben Evans
Investment Director
InHealth Ventures

Caroline Sai
European Coordinator of EIT Health Investor Network
EIT Health

Catherine Boule
Managing Partner
CapDecisif Management

Christian Soschner
CEO
CS Life Science Invest

Christoph Massner
Analyst
Earlybird

Donald Xu
Managing Director
Lynx Financial

João Ribas
Associate
Novo Holdings

Julian Vasilescu
Director of Licensing, Business Development
Roche Diagnostics

Luc Marengere
Managing Partner
TVM Capital Life Science

Markus Wanko
Managing Partner
IST CUBE

Matthieu Chareyre
Serial Angel Investor

Mirko Scherer
CEO
CoFeS China

Natalia Novac
Director, Emerging Technology & Innovation
Eli Lilly & Co

Neha Tanna
Principal
Joyance Partners

Patrick Burgermeister
Partner
KIZOO Technology Ventures

Stephen Kearney
Innovation – Life & Health
Hannover Re

Varun Gupta
Associate
Wellington Partners Venture Capital

Walter Stockinger
Managing Partner
Hadean Ventures

%d bloggers like this: